- Home Page
- Latest Updates
- Tumor Types
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Pipeline Molecules
- Research Education
- Research ADCs
- Research Apoptosis
- Research B cell
- Research BRAF
- Research HDIs
- Research Hedgehog
- Research HER Pathways
- Research VEGF
- Clinical Trials
- Resources
- Contact Us
Research Bcell
Related Resources for this page:
- Future Directions
- Antibody-Drug Conjugates
- Apoptosis
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- Non-Antibody Biologics
- Targeted Small Molecules
- Apoptosis
- Apoptotic pathways
- The Bcl-2 family
- Apoptosis
- Emerging therapeutic options
- Emerging therapeutic options
- Resisting apoptosis
- Gastric Cancer
- HER1/EGFR as a therapeutic target
- MAPK Signaling
- MEK Inhibitor (GDC-0973)
- Emerging therapeutic options
- PI3K Inhibitor (GDC-0941)
- Reactivating apoptosis
- PI3K/Akt/mTOR Signaling
- Therapeutic potential of HER pathways
- Traditional Monoclonal Antibodies
- B-cell Surface Proteins
- Glossary
- Emerging therapeutic options
- Emerging therapeutic options
- The evolving CLL treatment landscape
- Gastric Cancer
- HER Signaling
- HER1/EGFR as a therapeutic target
- HER2:HER3 dimer
- HER2 as a therapeutic target
- HER3 as a therapeutic target
- Emerging therapeutic options
- Obinutuzumab (GA101)
- Therapeutic potential of HER pathways
Share
Direct cell death
- A distinct mechanism for tumor destruction known as direct cell death has been identified and is an area of active research. This form of cell death involves homotypic cellular adhesion followed by non-autophagic lysosome–mediated cell death11
- Some monoclonal antibodies evaluated for the treatment of B-cell malignancies have been shown to induce enhanced direct cell death in vitro